> For the complete documentation index, see [llms.txt](https://www.thiamine.wiki/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.thiamine.wiki/biochemistry/sulbutiamine.md).

# sulbutiamine

{% hint style="info" %}
**Section:** Complete Biochemistry → Thiamine Derivatives\
**Reading level:** Technical, with a plain-language summary\
**Last reviewed:** October 2026 · **Evidence status:** Moderate (brain uptake in animals); limited (clinical outcomes)
{% endhint %}

## Summary

**Sulbutiamine** is a synthetic thiamine derivative made of **two ring-opened thiamine molecules joined by a disulfide bond**, each carrying an isobutyryl ester on its side chain. This makes it highly lipophilic. It was developed in Japan and has been used as a medicine for **asthenia** (fatigue and weakness) in France and some other countries. Elsewhere, it is sold as a supplement, often marketed as a "nootropic".

In rats, sulbutiamine **increases thiamine and thiamine phosphate esters in the brain**, unlike benfotiamine. Animal studies suggest effects on memory and on cholinergic, glutamatergic and dopaminergic signalling. Human evidence comes mainly from **older fatigue trials and small open-label studies**, with mixed results, and long-term safety data are limited.

## Key facts

| Property                       | Detail                                                                                              |
| ------------------------------ | --------------------------------------------------------------------------------------------------- |
| **Chemical name**              | O-Isobutyrylthiamine disulfide (bis-isobutyryl thiamine disulfide)                                  |
| **Formula**                    | C₃₂H₄₆N₈O₆S₂                                                                                        |
| **Molar mass**                 | ≈702.9 g/mol                                                                                        |
| **Class**                      | Disulfide dimer with ester groups                                                                   |
| **Activation**                 | Reduction of the disulfide bond and hydrolysis of the isobutyryl esters → two molecules of thiamine |
| **Brain uptake (animal data)** | Increases brain thiamine and its phosphate esters                                                   |
| **Main clinical use**          | Asthenia (fatigue), in some countries                                                               |

## Chemistry and activation

Sulbutiamine can be pictured as two thiamine molecules that have each been opened, given an isobutyryl ester on the side-chain oxygen, and then joined together through their sulfur atoms.

{% stepper %}
{% step %}

### Absorption

Its high lipophilicity allows passive diffusion across the gut wall and the blood–brain barrier.
{% endstep %}

{% step %}

### Reduction

The disulfide bond is reduced inside cells, giving two O-isobutyryl thiamine thiol molecules.
{% endstep %}

{% step %}

### Ester hydrolysis

Esterases remove the isobutyryl groups.
{% endstep %}

{% step %}

### Ring closure

The thiol forms close to thiamine, which is phosphorylated to TPP.
{% endstep %}
{% endstepper %}

## Brain uptake

In rats given sulbutiamine, brain concentrations of thiamine, TMP, TPP and ThTP increased. This contrasts with benfotiamine, which in mice raised blood and liver thiamine but not brain thiamine. Sulbutiamine is therefore often cited as the clearest example of a thiamine derivative designed to reach the central nervous system.

## Neurochemical effects in animals

| Finding                                                                      | Model | Strength     |
| ---------------------------------------------------------------------------- | ----- | ------------ |
| Improved long-term memory formation, possibly through cholinergic mechanisms | Mice  | **Limited**  |
| Modulation of glutamatergic and dopaminergic transmission in the cortex      | Rats  | **Limited**  |
| Increased brain thiamine phosphate esters                                    | Rats  | **Moderate** |

These findings come from a small number of older studies. Whether they reflect thiamine delivery or effects of sulbutiamine or its metabolites themselves is not clear.

## Clinical evidence

| Area                                                                                              | Study type                                                     | Findings                                                                      | Strength                                                   |
| ------------------------------------------------------------------------------------------------- | -------------------------------------------------------------- | ----------------------------------------------------------------------------- | ---------------------------------------------------------- |
| **Asthenia (functional fatigue)**                                                                 | Older clinical trials, mainly French                           | Reported improvements in fatigue                                              | **Limited**: older methods; few accessible controlled data |
| **Chronic post-infectious fatigue**                                                               | Randomized, double-blind, placebo-controlled (1999); two doses | Mixed results; no clear overall superiority over placebo at the main endpoint | **Limited**                                                |
| **Fatigue in multiple sclerosis**                                                                 | Open-label study (2017)                                        | Reduced fatigue scores                                                        | **Very limited** (no control group)                        |
| **Other conditions** (e.g. diabetic neuropathy, erectile dysfunction, depression-related fatigue) | Small studies, some in non-English journals                    | Variable                                                                      | **Very limited**                                           |

{% hint style="warning" %}
**Evidence note:** sulbutiamine is widely promoted online for memory, energy and mood. These claims rest mainly on animal studies and small or uncontrolled human studies. There is no robust controlled evidence that sulbutiamine improves cognition in healthy people.
{% endhint %}

## Safety

* Short-term clinical studies have generally reported sulbutiamine as **well tolerated**.
* **Long-term safety** data are limited, particularly at the doses sometimes used in non-medical "nootropic" settings.
* Because it acts on the central nervous system in animal studies, potential interactions with psychoactive medications have not been adequately studied.
* Regulatory status differs between countries (medicine in some, supplement in others).

## Evidence quality

| Claim type                              | Strength                                 |
| --------------------------------------- | ---------------------------------------- |
| Chemistry and activation                | **Strong**                               |
| Increased brain thiamine compounds      | **Moderate** (animal data)               |
| Neurochemical effects                   | **Limited** (few animal studies)         |
| Clinical benefit for fatigue            | **Limited and mixed**                    |
| Cognitive enhancement in healthy people | **Not supported** by controlled evidence |
| Long-term safety                        | **Limited**                              |

## Open questions

* Does sulbutiamine raise brain TPP in humans, and does this matter clinically?
* Are its reported central effects due to thiamine delivery or to other actions?
* Would modern, adequately powered trials confirm any benefit for fatigue?

## Related pages

* [Thiamine Derivatives (Overview)](broken://pages/44390ee2e231e4f690942c9b807cab9f6eb7272d)
* [TTFD (Fursultiamine)](broken://pages/d037fc57c35a037bf0b6fdbf558c95ab9a21412f)
* [Benfotiamine](broken://pages/75effe2f75d8702a4645b72eb76b7a3b69392e6d)
* [Thiamine Transporters](broken://pages/e114cfc2a7f363a679ae103c52c9089e5d2d0b24)

## References

1. Bettendorff L, Weekers L, Wins P, Schoffeniels E. Injectable sulbutiamine induces an increase in thiamine concentrations and thiamine phosphate esters in rat brain. *Biochemical Pharmacology*. 1990;40(11):2557–2560.
2. Volvert ML, et al. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. *BMC Pharmacology*. 2008;8:10.
3. Micheau J, et al. Chronic administration of sulbutiamine improves long term memory formation in mice: possible cholinergic mediation. *Pharmacology Biochemistry and Behavior*. 1985;23(2):195–198.
4. Trovero F, et al. Evidence for a modulatory effect of sulbutiamine on glutamatergic and dopaminergic cortical transmissions in the rat brain. *Neuroscience Letters*. 2000;292(1):49–53.
5. Tiev KP, Cabane J, Imbert JC. Treatment of chronic postinfectious fatigue: randomized double-blind study of two doses of sulbutiamine (400–600 mg/day) versus placebo. *La Revue de Médecine Interne*. 1999;20(10):912–918.
6. Sevim S, et al. Sulbutiamine shows promising results in reducing fatigue in patients with multiple sclerosis. *Multiple Sclerosis and Related Disorders*. 2017;16:40–43.

{% hint style="info" %}
**Editorial note:** This page describes mechanisms and published evidence. It is not medical advice and does not recommend doses. Suggest corrections or new sources via the feedback link.
{% endhint %}
